Fondation Rothschild, CHU de Marseille; Service de Neurologie (P.V.), CHU de Lille; Service de Neurologie (G.E.), CHU de Rennes; Service de Neurologie CHU de Dijon; Service de Neurologie CHU de Créteil; Service de Neurologie (P.L.), CHU de Montpellier; Service de Neurologie (L.M.), CHU de Limoges CHU de Caen; and INSERM UMR U1064 (D.A.L.), pp.21453-21457, 2002. ,
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.362, issue.5, pp.387-401, 2010. ,
DOI : 10.1056/NEJMoa0909494
URL : https://hal.archives-ouvertes.fr/hal-00617764
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.362, issue.5, pp.402-415, 2010. ,
DOI : 10.1056/NEJMoa0907839
URL : https://hal.archives-ouvertes.fr/hal-00617750
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Neurology, vol.13, issue.6, pp.545-556, 2014. ,
DOI : 10.1016/S1474-4422(14)70049-3
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.354, issue.9, pp.899-910, 2006. ,
DOI : 10.1056/NEJMoa044397
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS, Neurology, vol.68, issue.17, pp.1390-1401, 2007. ,
DOI : 10.1212/01.wnl.0000260064.77700.fd
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis, New England Journal of Medicine, vol.353, issue.4, pp.369-374, 2005. ,
DOI : 10.1056/NEJMoa051782
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab, New England Journal of Medicine, vol.353, issue.4, pp.375-381, 2005. ,
DOI : 10.1056/NEJMoa051847
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort, Journal of Neurology, vol.26, issue.30, pp.2981-2985, 2013. ,
DOI : 10.1007/s00415-013-7082-0
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy, Multiple Sclerosis Journal, vol.36, issue.10, pp.1381-1390, 2014. ,
DOI : 10.1177/1352458513477925
Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis A Clinical Practice Observational Study, European Neurology, vol.72, issue.3-4, pp.173-180, 2014. ,
DOI : 10.1159/000361044
Fingolimod after natalizumab and the risk of short-term relapse, Neurology, vol.82, issue.14, pp.1204-1211, 2014. ,
DOI : 10.1212/WNL.0000000000000283
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, Annals of Neurology, vol.82, issue.pt 12, pp.425-435, 2015. ,
DOI : 10.1002/ana.24339
Observatoire de la sclérose en plaques (OFSEP) Available at: http://www.ofsep.org/fr/la-cohorte, 2015. ,
EDMUS, a European database for multiple sclerosis., Journal of Neurology, Neurosurgery & Psychiatry, vol.55, issue.8, pp.671-676, 1992. ,
DOI : 10.1136/jnnp.55.8.671
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC489202
Clinical Epidemiology: How to Do Clinical Practice Research, p.496, 2006. ,
Levels of evidence: Taking Neurology(R) to the next level, Neurology, vol.72, issue.1, pp.8-10, 2009. ,
DOI : 10.1212/01.wnl.0000342200.58823.6a